RxDoctor Payments Data

Nou Her

Family · Paradise, CANPI 1013149996

Payments from drug & device makers

$5,086in general payments, 2019–2025

Across 182 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$737
  • Medtronic$274
  • Kyowa Kirin, Inc.$195
  • GSK$192
  • Exact Sciences$174
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,086100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,086 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin124$82,603
OzempicSemaglutide62$63,187
TrulicityDulaglutide52$48,075
RybelsusSemaglutide36$35,865
Breo ElliptaFluticasone/Vilanterol64$27,765
FarxigaDapagliflozin Propanediol30$17,200
MounjaroTirzepatide15$15,625
EliquisApixaban24$14,809
JanuviaSitagliptin Phosphate17$13,273
Victoza 3-PakLiraglutide11$11,993
Combivent RespimatIpratropium/Albuterol Sulfate18$9,102
Incruse ElliptaUmeclidinium Bromide24$8,074
Albuterol Sulfate HfaAlbuterol Sulfate276$7,840
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$6,060
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$3,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$737$99,05398 claims
Boehringer IngelheimJardiance, Combivent Respimat$128$91,705142 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$140$64,54995 claims
GSKBreo Ellipta, Incruse Ellipta$192$35,83988 claims
AstraZenecaFarxiga$85$17,20030 claims
PfizerEliquis$102$14,80924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Paradise

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →